Molecular Testing in Breast Cancer: Current Status and Future Directions

Keyphrases

• Breast Cancer 100%
• Molecular Diagnostics 100%
• Pathologist 66%
• Oncotype DX 66%
• Immunohistochemistry 33%
• Patient Care 33%
• Invasive Breast Cancer 33%
• Prognostic Value 33%
• Ductal Carcinoma in Situ 33%
• Predictive Value 33%
• Tumor mutational Burden 33%
• Immune Checkpoint Inhibitors 33%
• NTRK Fusion 33%
• Microsatellite Instability-high (MSI-H) 33%
• Programmed Death-ligand 1 (PD-L1) 33%
• Mismatch Repair 33%
• Hopefulness 33%
• Cell-free DNA (cfDNA) 33%
• PIK3CA mutation 33%
• Therapeutic Value 33%
• Circulating Tumor Cells 33%
• Practical Utility 33%
• Molecular Assay 33%
• Gene Testing 33%
• Gene Panel Sequencing 33%
• DNA Assay 33%
• Anti-programmed Death 1 33%
• MammaPrint 33%
• SP142 33%
• Prosigna 33%
• Breast Cancer Index 33%

Medicine and Dentistry

• Breast Cancer 100%
• Neoplasm 50%
• Pathologist 50%
• Intraductal Carcinoma 50%
• Oncotype DX 50%
• Immunohistochemistry 25%
• Patient Care 25%
• Clinician 25%
• Next Generation Sequencing 25%
• Immune Checkpoint Inhibitor 25%
• Microsatellite Instability 25%
• DNA Mismatch Repair 25%
• Cell-Free DNA 25%